AnaptysBio Inc (ANAB)
25.06
-0.40
(-1.59%)
USD |
NASDAQ |
May 17, 16:00
25.06
0.00 (0.00%)
After-Hours: 20:00
AnaptysBio Cash from Financing (Quarterly): -13.63M for March 31, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -13.63M |
| December 31, 2023 | -5.159M |
| September 30, 2023 | -3.072M |
| June 30, 2023 | -13.49M |
| March 31, 2023 | -37.57M |
| December 31, 2022 | 1.949M |
| September 30, 2022 | 37.03M |
| June 30, 2022 | 0.432M |
| March 31, 2022 | 4.609M |
| December 31, 2021 | 251.34M |
| September 30, 2021 | 0.241M |
| June 30, 2021 | 0.554M |
| March 31, 2021 | 0.167M |
| December 31, 2020 | 0.126M |
| September 30, 2020 | 0.263M |
| June 30, 2020 | 0.071M |
| March 31, 2020 | -1.339M |
| December 31, 2019 | -0.111M |
| September 30, 2019 | -1.421M |
| Date | Value |
|---|---|
| June 30, 2019 | -1.66M |
| March 31, 2019 | -1.301M |
| December 31, 2018 | -1.372M |
| September 30, 2018 | 226.60M |
| June 30, 2018 | -0.477M |
| March 31, 2018 | -1.383M |
| December 31, 2017 | 212.39M |
| September 30, 2017 | 0.30M |
| June 30, 2017 | -0.938M |
| March 31, 2017 | 80.70M |
| December 31, 2016 | 9.669M |
| September 30, 2016 | -0.379M |
| June 30, 2016 | -0.387M |
| March 31, 2016 | -0.275M |
| December 31, 2015 | -0.892M |
| September 30, 2015 | 40.27M |
| June 30, 2015 | -0.014M |
| March 31, 2015 | 0.043M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-37.57M
Minimum
Mar 2023
251.34M
Maximum
Dec 2021
10.97M
Average
0.0985M
Median
Cash from Financing (Quarterly) Benchmarks
| XOMA Corp | -4.956M |
| Fate Therapeutics Inc | 95.49M |
| Ocular Therapeutix Inc | 321.22M |
| Apellis Pharmaceuticals Inc | 108.21M |
| Sutro Biopharma Inc | -3.429M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -37.25M |
| Cash from Investing (Quarterly) | 68.62M |
| Free Cash Flow | -134.14M |
| Free Cash Flow Per Share (Quarterly) | -1.391 |
| Free Cash Flow to Equity (Quarterly) | -37.28M |
| Free Cash Flow Yield | -20.09% |